Cancer Research AACR Legacy  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 3574-3582, September 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mimnaugh, E. G.
Right arrow Articles by Gram, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mimnaugh, E. G.
Right arrow Articles by Gram, T. E.

Differential Effects of Anthracycline Drugs on Rat Heart and Liver Microsomal Reduced Nicotinamide Adenine Dinucleotide Phosphate-dependent Lipid Peroxidation

Edward G. Mimnaugh1, Michael A. Trush, Erika Ginsburg and Theodore E. Gram

Laboratory of Medicinal Chemistry and Biology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205

Rat liver microsomes have previously been utilized as a model biological system to study the activation of Adriamycin to the semiquinone free radical intermediate and the enhancement by Adriamycin of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidation and oxygen consumption. Incubating rat liver microsomes with Adriamycin or other structurally similar benzanthraquinone anticancer drugs resulted in marked stimulation of NADPH-dependent lipid peroxidation. Carminomycin and 4-demethoxydaunorubicin were considerably more potent than Adriamycin, while daunorubicin, deacetyladriamycin, N-dimethyl-adriamycin, aclacinomycin A, adriamycin 14-nicotinate, and steffimycin were approximately equipotent to Adriamycin in this test system. In contrast, lapachol, anthragallol, alkylaminoanthracenedione, mitomycin C, streptonigrin, 5-iminodaunorubicin, and the Adriamycin:DNA complex potently inhibited microsomal lipid peroxidation. Methotrexate, cyclophosphamide, 5-fluorouracil, nogalamycin, or rubidazone had little or no effect. {alpha}-Tocopherol-deficient rat heart microsomes but not control heart microsomes were susceptible to increased NADPH-dependent lipid peroxidation (up to 10-fold) when incubated with Adriamycin or other anthracycline analogs which stimulated peroxidation in liver microsomes. The rate of NADPH oxidation in the presence of microsomes was enhanced 4-fold by either Adriamycin or daunorubicin; lapachol, anthragallol, aminoanthracenedione, and 5-iminodaunorubicin at concentrations which inhibited lipid peroxidation had no effect on NADPH oxidation. NADPH:cytochrome P-450 reductase activity was unaltered by those drugs which either stimulated or inhibited peroxidation. These results suggest that although several Adriamycin-like anthracycline drugs dramatically stimulated NADPH-dependent, reactive oxygen-mediated lipid peroxidation in rat liver and heart microsomes, other quinone-containing anticancer drugs do not enhance lipid peroxidation. Interestingly, there appears to be a direct correlation between the ability of certain anthracyclines to stimulate heart or liver microsomal lipid peroxidation and the effects of these drugs in other cardiotoxicity model systems.

1 To whom requests for reprints should be addressed.

Received 10/19/81. Accepted 6/ 7/82.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
T. D. SHENKENBERG and D. D. VON HOFF
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
Ann Intern Med, July 1, 1986; 105(1): 67 - 81.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.